The 20 references in paper O. Shakhmatova O., О. Шахматова О. (2017) “ФОНДАПАРИНУКС В ЛЕЧЕНИИ ОСТРОГО КОРОНАРНОГО СИНДРОМА // FONDAPARINUX IN THE TREATMENT OF ACUTE CORONARY SYNDROME” / spz:neicon:aterotromboz:y:2017:i:1:p:16-27

1
Roffi M, Patrono C, Collet JP, et al. 2015 ESCguidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J,2016, 37: 267-315.
(check this in PDF content)
2
Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am CollCardiol,2014, 64: e139-228. ТАБЛИЦА (окончание).Применение фондапаринукса при разных типах ОКС согласно рекомендациям международных кардиологических ассоциаций [1, 2, 18, 19] Стратегия лечения Рекомендации Европейской Ассоциации КардиологовРекомендации АНА/АСС 123 ОтсутствиеФондапаринукс назначаетсяНет соответствующего раздела реперфузионнойв том же режиме, что и прив рекомендациях. терапиитромболизисе.
(check this in PDF content)
3
Warkentin TE, Chakraborty AK, Sheppard JA, Griffin DK. The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndrome. Thrombosis and Haemostasis,2012, 108: 394-396.
(check this in PDF content)
4
Simoons ML, Bobbink IW, Boland J, et al. A dose-finding study of fondaparinux in patients with non-STsegment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol, 2004, 43: 2183-2190.
(check this in PDF content)
5
Yusuf S, Mehta SR, Chrolavicius S, et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med,2006, 354: 1464-1476.
(check this in PDF content)
6
Jolly SS, Faxon DP, Fox KA, Afzal R, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. J Am Coll Cardiol, 2009 Jul 28, 54(5): 468-76.
(check this in PDF content)
7
Fox KA, Bassand JP, Mehta SR, Wallentin L, Theroux P, Piegas LS, Valentin V, Moccetti T, Chrolavicius S, Afzal R, Yusuf S, OASIS 5 Investigators. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med,2007, 147: 304-310.
(check this in PDF content)
8
Budaj A, Eikelboom JW, Mehta SR, Afzal R, et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J, [Internet]. 2009 Mar [cited 2016 Aug 10], 30(6): 655-61. Available from: http:// eurheartj.oxfordjournals.org/content/ehj/30/6/655.full.pdf.
(check this in PDF content)
9
The FUTURA/OASIS-8 Trial Group. Low-Dose vs Standard-Dose Unfractionated Heparin for Percutaneous Coronary Intervention in Acute Coronary Syndromes Treated WithFondaparinux. The FUTURA/OASIS-8 RandomizedTrial. JAMA, 2010, 304(12): 1339-1349.
(check this in PDF content)
10
Szummer K, Oldgren J, Lindhagen L, et al. Association between the use of fondaparinux vs low-molecularweight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction. JAMA,2015, 313: 707-716.
(check this in PDF content)
11
Qiao J, Zhang X, Zhang J, et al. Comparison between Fondaparinux and Low-Molecular-Weight Heparin in Patients with Acute Coronary Syndrome: A MetaAnalysis. Cardiology,2016, 133: 163-172.
(check this in PDF content)
12
Yan HB, Song L, Liu R, et al. Comparison of safety and efficacy between fondaparinux and nadroparin in non-ST elevation acute coronary syndromes. Chin Med J (Engl), 2011, 124: 879-886.
(check this in PDF content)
13
Shah S, Khajuria V, Tandon VR, Gillani ZH, Lal M. Comparative evaluation of efficacy, safety and haemostatic parameters of enoxaparin and fondaparinux in unstable coronary artery disease. J Clin Diagn Res, 2014, 8: 31-34.
(check this in PDF content)
14
Puymirat E, Schiele F, Ennezat PV, et al. Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non— ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010. Eur Heart J Acute Cardiovasc Care, 2015, 4: 211-219.
(check this in PDF content)
15
Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J,2011, 32: 1854-1864.
(check this in PDF content)
16
Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA,2006, 295: 1519-1530.
(check this in PDF content)
17
Navarese EP, Andreotti F, Kolodziejczak M, et al. Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Thromb Haemost,2015, 114: 933-944.
(check this in PDF content)
18
Steg PhG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012 33: 2569-2619.
(check this in PDF content)
19
O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of STElevation Myocardial Infarction. Circulation, 2013, 127: e362-e425.
(check this in PDF content)
20
Washam JB, Herzog CA, Beitelshees AL, et al. Pharmacotherapy in Chronic Kidney Disease Patients Presenting With Acute Coronary Syndrome. A Scientific Statement From the American Heart Association. Circulation, 2015, 131: 1123-1149.
(check this in PDF content)